Journal article
Evidence for beta(1)-Adrenergic Receptor Involvement in Amygdalar Corticotropin-Releasing Factor Gene Expression: Implications for Cocaine Withdrawal
Neuropsychopharmacology (New York, N.Y.), v 34(5), pp 1135-1148
01 Apr 2009
PMID: 18596687
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
We previously showed that betaxolol, a selective beta(1)-adrenergic receptor antagonist, administered during early phases of cocaine abstinence, ameliorated withdrawal-induced anxiety and blocked increases in amygdalar beta(1)-adrenergic receptor expression in rats. Here, we report the efficacy of betaxolol in reducing increases in gene expression of amygdalar corticotropin-releasing factor (CRF), a peptide known to be involved in mediating 'anxiety-like' behaviors during initial phases of cocaine abstinence. We also demonstrate attenuation of an amygdalar beta(1)-adrenergic receptor-mediated cell-signaling pathway following this treatment. Male rats were administered betaxolol at 24 and 44 h following chronic cocaine administration. Animals were euthanized at the 48-h time point and the amygdala was microdissected and processed for quantitative reverse transcriptase-polymerase chain reaction and/or western blot analysis. Results showed that betaxolol treatment during early cocaine withdrawal attenuated increases in amygdalar CRF gene expression and cyclic adenosine monophosphate-dependent protein kinase regulatory and catalytic subunit (nuclear fraction) protein expression. Our data also reveal that beta(1)-adrenergic receptors are on amygdalar neurons, which are immunoreactive for CRF. The present findings suggest that the efficacy of betaxolol treatment on cocaine withdrawal-induced anxiety may be related, in part, to its effect on amygdalar beta(1)-adrenergic receptor, modulation of its downstream cell-signaling elements and CRF gene expression.
Metrics
Details
- Title
- Evidence for beta(1)-Adrenergic Receptor Involvement in Amygdalar Corticotropin-Releasing Factor Gene Expression: Implications for Cocaine Withdrawal
- Creators
- Carla A. Rudoy - Thomas Jefferson UniversityArith-Ruth S. Reyes - Thomas Jefferson UniversityElisabeth J. Van Bockstaele - Thomas Jefferson University
- Publication Details
- Neuropsychopharmacology (New York, N.Y.), v 34(5), pp 1135-1148
- Publisher
- Springer Nature
- Number of pages
- 14
- Grant note
- NIH; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA R01DA009082 / NATIONAL INSTITUTE ON DRUG ABUSE; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA); European Commission F31DA019311; DA15395; DA009082 / Ruth L Kirschstein National Research Service Award; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA National Institute on Drug Abuse (NIDA); United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA)
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Pharmacology and Physiology
- Web of Science ID
- WOS:000264178600006
- Scopus ID
- 2-s2.0-62349117529
- Other Identifier
- 991021903406904721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Neurosciences
- Pharmacology & Pharmacy
- Psychiatry